236 related articles for article (PubMed ID: 29739463)
21. Effectiveness of public deliberation methods for gathering input on issues in healthcare: Results from a randomized trial.
Carman KL; Mallery C; Maurer M; Wang G; Garfinkel S; Yang M; Gilmore D; Windham A; Ginsburg M; Sofaer S; Gold M; Pathak-Sen E; Davies T; Siegel J; Mangrum R; Fernandez J; Richmond J; Fishkin J; Siu Chao A
Soc Sci Med; 2015 May; 133():11-20. PubMed ID: 25828260
[TBL] [Abstract][Full Text] [Related]
22. The public funding of expensive cancer therapies: synthesizing the "3Es"--evidence, economics, and ethics.
Kirby J; Somers E; Simpson C; McPhee J
Organ Ethic; 2008; 4(2):97-108. PubMed ID: 18839752
[TBL] [Abstract][Full Text] [Related]
23. Which public and why deliberate?--A scoping review of public deliberation in public health and health policy research.
Degeling C; Carter SM; Rychetnik L
Soc Sci Med; 2015 Apr; 131():114-21. PubMed ID: 25770463
[TBL] [Abstract][Full Text] [Related]
24. Disinvestment policy and the public funding of assisted reproductive technologies: outcomes of deliberative engagements with three key stakeholder groups.
Hodgetts K; Hiller JE; Street JM; Carter D; Braunack-Mayer AJ; Watt AM; Moss JR; Elshaug AG;
BMC Health Serv Res; 2014 May; 14():204. PubMed ID: 24885716
[TBL] [Abstract][Full Text] [Related]
25. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
Hanley GE; Morgan S; Hurley J; van Doorslaer E
Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
[TBL] [Abstract][Full Text] [Related]
26. Public values and guiding principles for implementing epitope compatibility in kidney transplantation allocation criteria: results from a Canadian online public deliberation.
Slomp C; Edwards L; Burgess M; Sapir-Pichhadze R; Keown P; Bryan S
BMC Public Health; 2023 May; 23(1):844. PubMed ID: 37165330
[TBL] [Abstract][Full Text] [Related]
27. Ethical considerations relating to healthcare resource allocation decisions.
Olver I; Dodds S; Kenner J; Kerridge I; McGovern K; Milligan E; Mortimer R;
Intern Med J; 2019 Nov; 49(11):1364-1367. PubMed ID: 31713342
[TBL] [Abstract][Full Text] [Related]
28. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
MacLeod TE; Harris AH; Mahal A
Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
[TBL] [Abstract][Full Text] [Related]
29. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding.
Sinclair S; Hagen NA; Chambers C; Manns B; Simon A; Browman GP
Health Policy; 2008 May; 86(2-3):381-90. PubMed ID: 18243395
[TBL] [Abstract][Full Text] [Related]
30. Drug formulary decision-making in two regional health authorities in British Columbia, Canada.
Armstrong K; Mitton C; Carleton B; Shoveller J
Health Policy; 2008 Dec; 88(2-3):308-16. PubMed ID: 18508151
[TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical policies in Canada: another example of federal-provincial discord.
Anis AH
CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
[TBL] [Abstract][Full Text] [Related]
32. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
33. Citizens' juries in planning research priorities: process, engagement and outcome.
Gooberman-Hill R; Horwood J; Calnan M
Health Expect; 2008 Sep; 11(3):272-81. PubMed ID: 18816323
[TBL] [Abstract][Full Text] [Related]
34. "There is always a better way": Managing uncertainty in decision making about new cancer drugs in Canada.
Driedger SM; Cooper E; Annable G; Brouwers M
Int J Health Plann Manage; 2018 Apr; 33(2):e485-e499. PubMed ID: 29417619
[TBL] [Abstract][Full Text] [Related]
35. Biobanking, public consultation, and the discursive logics of deliberation: five lessons from British Columbia.
Walmsley H
Public Underst Sci; 2010 Jul; 19(4):452-68. PubMed ID: 20977183
[TBL] [Abstract][Full Text] [Related]
36. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
37. [Is the price of cancer drugs related to the cost of develo-pment and production or to the economic value of their clincal efficacy?].
Russi A; Serena M; Palozzo AC
Recenti Prog Med; 2016 Apr; 107(4):181-5. PubMed ID: 27093327
[TBL] [Abstract][Full Text] [Related]
38. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
Leigh S; Granby P
Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
[TBL] [Abstract][Full Text] [Related]
39. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
Boulet AP; Tessier G
Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
[TBL] [Abstract][Full Text] [Related]
40. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
